Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia.

ABSTRACT:

Importance

Patients with refractory hypercholesterolemia who do not achieve their guideline-defined low-density lipoprotein cholesterol (LDL-C) thresholds despite treatment with maximally tolerated combinations of lipid-lowering therapies (LLTs) have an increased risk of atherosclerotic cardiovascular disease (ASCVD).

Objective

To evaluate longer-term efficacy and safety of evinacumab in patients with refractory hypercholesterolemia.

Design, setting, and participants

This randomized clinical trial included a 2-week screening period followed by a 16-week double-blind treatment period (DBTP) for subcutaneous regimens (evinacumab, 450 mg, once weekly [QW]; evinacumab, 300 mg, QW; evinacumab, 300 mg, every 2 weeks; or placebo QW) or a 24-week DBTP for intravenous regimens

SUBMITTER: Rosenson RS 

PROVIDER: S-EPMC10500429 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature